æther THERAPEUTICS
Company Details
Status: Private
Employees: 1-10
Location:
4200 Marathon Blvd. Suite 200
Type:
sample
Technology:
sample
About: The statistics are overwhelming: more than 130 people a day die from opioid related drug overdoses. In 2020 in the US alone, 2.7 million people aged 12 or older had Opioid Use Disorder (OUD) and 4.2 million people entered a drug rehabilitation program.
While treatment programs and rescue medications are critical, æther THERAPEUTICS is focusing our efforts upstream: preventing addiction and creating a more effective treatment of OUD. æther THERAPEUTICS' main candidate is Low Dose 6β-Naltrexol (ATX-001). Animal models indicate that ATX-001 may prevent opioid dependence while not blocking pain relief or causing withdrawal & other adverse effects.
Our vision is a world where the devastating effects of opioid addiction are alleviated, leading to:
• Safer opioid pain therapy without the fear of addiction,
• Cessation of opioid addiction
• Prevention of Neonatal Opioid Withdrawal Syndrome (NOWS)
æther THERAPEUTICS is focused on our vision, driven by innovation, embraces lean operations and engaged with urgency.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
æther THERAPEUTICS | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.